With that in mind, let's consider two high-yield dividend stocks worth investing in: Pfizer (NYSE: PFE) and Medical ...

Consider the company's prospects in oncology. Pfizer acquired Seagen ... obligations to grant it more financial flexibility. MPT's turnaround story is in full swing. That's why the stock has ...

Pharma names such as Pfizer and BASF caught investor attention ... highlights strong market participation amid improving trade prospects and easing geopolitical risks, signaling optimism for ...

Pfizer faces several headwinds, including patent cliffs, regulatory risks, and a setback in obesity drug development. Click ...

Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals ...

Pfizer will pay China’s 3SBio $1.25 billion up front to access a cancer drug that could rival Akeso and Summit’s closely ...

Morgan Stanley maintained an 'overweight' rating on ITC Ltd. with a target price of Rs 500, citing strong topline growth ...

Pfizer has said it will shed staff and cut its operating costs by around $3.5 billion, as it faces a shortfall in COVID-19 vaccine and treatment sales, with revenues now expected to be down around ...

May 14, 2025 Alnylam drops Covid vaccine patent case against Pfizer, BioNTech for now Biotech company Alnylam Pharmaceuticals conceded defeat for now in a lawsuit against Pfizer and BioNTech over ...

Pfizer placed a $6.7 billion bet on the outcome of two phase 3 trials of Arena Pharmaceuticals' etrasimod in ulcerative colitis (UC) when it acquired the company earlier this year, and the gamble ...